Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 5/20 | 0.40 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23549985 | 0.87 | DHFR (0.39) | HRH4DHFRS100BPDE2ANPBWR1 | |
| SCHEMBL165551 | 0.84 | PRMT1 (0.38) | HRH4DHFRNR1H2NR1H3 | |
| SCHEMBL3485526 | 0.81 | L3MBTL1 (0.44) | HRH4DHFRS100BNR1H2NR1H3 | |
| SCHEMBL23549967 | 0.79 | CES2 (0.42) | DHFRPDE2ACRHR1FABP4FABP5 | |
| SCHEMBL170653 | 0.78 | ESR1 (0.49) | HRH4ESR1PDE2AKIF11 | |
| SCHEMBL28262148 | 0.77 | HRH4 (0.33) | HRH4DHFRNR1H2NR1H3CRHR1 | |
| SCHEMBL9258889 | 0.75 | ALDH1A1 (0.42) | S100BCRHR1 | |
| SCHEMBL11503523 | 0.75 | RARA (0.46) | S100BCRHR1 | |
| SCHEMBL20104551 | 0.75 | MAPT (0.34) | DHFRS100BPDE2ACRHR1 | |
| SCHEMBL3484862 | 0.75 | ALDH3A1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | HRH4 400/4885DHFR 2540/4885S100B 4416/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | HRH4 2392/4885DHFR 119/4885S100B 2225/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | HRH4 2144/4885DHFR 1075/4885S100B 4120/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | HRH4 2392/4885DHFR 119/4885S100B 2225/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | HRH4 1479/4885DHFR 1654/4885S100B 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.